The treatment of metastatic renal cell carcinoma (mRCC) has rapidly evolved; however, the progress made in the field is heavily contingent upon timely and efficient accrual to clinical trials. While a substantial proportion of accrual occurs at tertiary care centers, community sites are playing an increasing role in patient recruitment. In this article, we discuss strategies to optimize collaborations between academic and community sites to facilitate clinical research. Further, as the role of biomarker discovery has become increasingly important in tailoring therapy, we will discuss opportunities to bridge diverse accrual sites for the purpose of translational research.
Journal of clinical medicine. 2020 May 17*** epublish ***
Nicholas J Salgia, Errol J Philip, Mohammadbagher Ziari, Kelly Yap, Sumanta Kumar Pal
Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91107, USA., University of California San Francisco School of Medicine, San Francisco, CA 94143, USA., Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Corona, CA 92879, USA., Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, South Pasadena, CA 91030, USA.